ORIVISE INSIGHTS
Practical thinking on diagnostics development, risk and readiness.
Short perspectives for founders, R&D teams, investors and academic translation teams working at the point where strong science must become a credible development proposition.
Working once is not the same as being development-ready.
Why reproducibility, sample variability, stability and transfer assumptions need to be tested before feasibility is mistaken for readiness.
Coming soonThe hidden cost of generating data before defining the decision.
What happens when assay development runs ahead of the question it is meant to answer — and how to reset the decision framework before rework compounds.
Coming soonWhy bioconjugation problems are usually discovered too late.
Conjugate instability and inconsistency are common root causes of assay variability — and the most frequently missed at feasibility stage.
Coming soonWhat a technical data room needs to actually show.
The gap between what a pitch deck claims and what the underlying data supports is exactly where independent technical due diligence adds the most value.
Coming soonWhy early feasibility data often fails during transfer.
Transfer exposes the assumptions that were not tested when the programme was still cheap enough to change direction.
Coming soonGood science still needs a fundable development story.
Grant and partner conversations require evidence, risk logic and credible milestones — not only promising results.
Coming soonWorking on an early-stage diagnostic programme?
Get independent technical input on feasibility, risks and next steps.